8-K: Tonix Pharmaceuticals Announces Positive Data for Mpox and Smallpox Vaccine Candidate TNX-801

Tonix Pharmaceuticals reports that its TNX-801 vaccine candidate demonstrates less virulence than older vaccines in immune-compromised mice, supporting its potential for mpox and smallpox prevention.

Summary

• Tonix Pharmaceuticals announced the publication of data in the peer-reviewed journal mSphere, demonstrating that their TNX-801 vaccine candidate is less virulent than 20th-century vaccinia vaccines in immune-compromised mice.
• The company believes this tolerability data supports the use of TNX-801 as a potential vaccine to control the spread of mpox Clade Ib and Clade IIb.
• TNX-801 has previously shown the ability to protect animals from a lethal challenge with Clade Ia monkeypox.
• The vaccine is based on horsepox and is designed to be a single-dose vaccine, potentially offering higher community protection rates.
• Tonix has received feedback from the FDA on their pre-Investigational New Drug Application for TNX-801.
• The company is collaborating with Bilthoven Biologics for GMP manufacturing and with the Kenya Medical Research Institute for a Phase I clinical study.

Sentiment

Score: 7

Explanation: The document presents positive pre-clinical data for a vaccine candidate, but it also acknowledges the risks and uncertainties associated with drug development. The sentiment is cautiously optimistic.

Positives

• TNX-801 shows significantly reduced virulence compared to older vaccines, suggesting a safer profile.
• The single-dose nature of TNX-801 could lead to better community protection due to reduced drop-out rates.
• The vaccine has demonstrated efficacy in protecting animals from lethal monkeypox challenges.
• Collaborations with Bilthoven Biologics and KEMRI indicate progress towards manufacturing and clinical trials.
• The vaccine is based on horsepox, which is believed to be more closely related to Dr. Jenners vaccine than 20th Century vaccinia viruses.

Negatives

• The document primarily focuses on pre-clinical data, and human trials are still needed to confirm safety and efficacy.
• The company is still in the process of seeking regulatory approvals for TNX-801.
• The document mentions the need for additional financing, which could be a risk.

Risks

• The development of TNX-801 is subject to regulatory approvals, which may not be granted.
• Clinical trials may not yield positive results, and the vaccine may not be effective in humans.
• The company may face challenges in manufacturing and distributing the vaccine at scale.
• There is competition from other companies developing mpox and smallpox vaccines.
• The company's need for additional financing could dilute existing shareholders.

Future Outlook

The company expects an FDA decision on the acceptance of the NDA for TNX-102 SL in December 2024 and a decision on NDA approval in 2025. They also plan to initiate enrollment in the OASIS study for TNX-102 SL in the fourth quarter. Tonix intends to continue the development of TNX-801 and other pipeline candidates.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that addressing the new Clade Ib mpox outbreak and the ongoing spread of Clade IIb mpox may require a single dose mpox vaccine that provides durable protection.
• The company believes that the new tolerability data support the idea that TNX-801 is a candidate vaccine to control the ongoing PHEICs with mpox Clade Ib and mpox Clade IIb.

Industry Context

The announcement comes amid ongoing global concerns about mpox outbreaks and the need for effective vaccines. The development of a single-dose vaccine with improved tolerability could be a significant advancement in the field. The company is also working on a COVID-19 vaccine candidate, TNX-1800, which is part of the NIH's Project NextGen.

Comparison to Industry Standards

• The document compares TNX-801 to older vaccinia vaccines used in the eradication of smallpox, highlighting its reduced virulence.
• It also contrasts TNX-801 with the FDA-approved mpox vaccine Jynneos, which requires two doses and provides a relatively short duration of protection.
• The document mentions ACAM2000, a live, replicating vaccinia vaccine for prevention of mpox, as a comparator.
• Pre-clinical results from an mRNA vaccine are mentioned, showing some protection from a Clade I monkeypox challenge, but with multiple break-through lesions in vaccinated animals.

Stakeholder Impact

• Shareholders may view the positive data as a positive development for the company.
• Employees may be encouraged by the progress of the vaccine candidate.
• The development of a new vaccine could benefit public health by providing a new tool to combat mpox and smallpox.
• The company's collaborations with Bilthoven Biologics and KEMRI could lead to new partnerships and opportunities.

Next Steps

• Tonix plans to continue the development of TNX-801, including clinical trials.
• The company expects an FDA decision on the acceptance of the NDA for TNX-102 SL in December 2024.
• Tonix plans to initiate enrollment in the OASIS study for TNX-102 SL in the fourth quarter.

Key Dates

Keywords

TNX-801, mpox, smallpox, vaccine, horsepox, vaccinia, immunocompromised, clinical trials, public health emergency, single-dose